LifeSci Capital analyst Patrick Dolezal raised the firm’s price target on Avadel Pharmaceuticals to $26 from $17 and keeps an Outperform rating on the shares after the company received final FDA approval of Lumryz for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. Given recent financing action, Avadel is "poised to deliver a robust Lumryz launch," the analyst tells investors.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVDL:
- Avadel Pharmaceuticals price target raised to $14 from $12 at Needham
- Avadel Pharmaceuticals price target raised to $16 from $14.50 at Ladenburg
- Avadel price target raised to $17.50 from $14 at H.C. Wainwright
- Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy
- Avadel Pharmaceuticals announces final FDA approval of LUMRYZ
